Robert E. Desjardins
Fondatore presso Drais Pharmaceuticals Inc.
Profilo
Robert E.
Desjardins is the founder of AkaRx, Inc. (founded in 2005) and Drais Pharmaceuticals Inc. (founded in 2007).
At AkaRx, Inc., he held the title of President & Chief Executive Officer from 2005 to 2010.
At Drais Pharmaceuticals Inc., he currently holds the title of Director.
In addition to his founding positions, Dr. Desjardins has held former jobs at Georgetown University as an Adjunct Professor, The Burroughs Wellcome Fund as Head-Anti-Infective Clinical Research, and Lederle Pharmaceuticals as a Principal.
Dr. Desjardins obtained a doctorate degree from Loyola University of Chicago.
Posizioni attive di Robert E. Desjardins
Società | Posizione | Inizio |
---|---|---|
Drais Pharmaceuticals Inc.
Drais Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ. | Fondatore | 01/01/2007 |
Precedenti posizioni note di Robert E. Desjardins
Società | Posizione | Fine |
---|---|---|
Lederle Pharmaceuticals | Corporate Officer/Principal | - |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Direttore Tecnico/Scientifico/R&S | 06/05/2011 |
Georgetown University | Corporate Officer/Principal | - |
AkaRx, Inc.
AkaRx, Inc. Pharmaceuticals: MajorHealth Technology AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ. | Fondatore | - |
Formazione di Robert E. Desjardins
Loyola University of Chicago | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
AkaRx, Inc.
AkaRx, Inc. Pharmaceuticals: MajorHealth Technology AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ. | Health Technology |
Drais Pharmaceuticals Inc.
Drais Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ. | Health Technology |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
Lederle Pharmaceuticals |
- Borsa valori
- Insiders
- Robert E. Desjardins